Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00370409
Other study ID # 8525
Secondary ID
Status Completed
Phase N/A
First received August 30, 2006
Last updated July 31, 2008
Start date January 2006
Est. completion date June 2008

Study information

Verified date July 2008
Source hahid Beheshti University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority Iran: Ethics Committee
Study type Interventional

Clinical Trial Summary

Late vitreous hemorrhage in postvitrectomized diabetic eyes may be due to fibrovascular tuft formation in sclerotomy sites. Cryotherapy of sclerotomy sites may prevent bleeding by regressing the fibrovascular tuft. This study will detect the safety and efficacy of cryotherapy of sclerotomy sites for prevention of late vitreous hemorrhage in vitrectomized diabetic eyes.


Recruitment information / eligibility

Status Completed
Enrollment 112
Est. completion date June 2008
Est. primary completion date February 2008
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Diabetic retinopathy cases undergoing vitrectomy

Exclusion Criteria:

- History of deep vitrectomy or cataract surgery

- Renal failure

- Silicone oil injection during surgery

- Early rebleeding

- History of antithrombotic drugs usage

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms

  • Hemorrhage
  • Late Postvitrectomy Diabetic Hemorrhage.

Intervention

Procedure:
Cryotherapy
Cryotherapy of both sides of sclerotomy sites was done for 6 seconds after complition of operation.

Locations

Country Name City State
Iran, Islamic Republic of Ophthalmic Research Center Tehran

Sponsors (1)

Lead Sponsor Collaborator
hahid Beheshti University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevention of late vitreous hemorrhage in postvitrectomized diabetic eyes 6 months No
Secondary Incidence of late vitreous hemorrhage in the cryo group. 6 months No
Secondary Incidence of late vitreous hemorrhage in the control group. 6 months No
Secondary Comparing incidence of late vitreous hemorrhage in both groups. 6 months No